...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Email this morning

I agree with your thoughts Nb, the only reason I have shares in these companies is because I also think the science seems to have increasing promise and there is strong outside validation supporting this. Lousy management is the only reason I don't have a lot more shares in these companies, especially at these pathetic valuations.

Share
New Message
Please login to post a reply